Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1663 participants.

Also called NCT01336023

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,663 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01336023
  • EudraCT 2010-021560-15
Other papers using this trial's data
  • A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges Diabetes technology & therapeutics, 2017-04 DOI, PubMed 28282219, PMC5399738 In the PMC Open Access subset under CC BY-NC.
  • Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes The lancet. Diabetes & endocrinology, 2014-11 DOI, PubMed 25190523
  • IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test Journal of diabetes science and technology, 2015-10-06 DOI, PubMed 26443290, PMC4773967 In the PMC Open Access subset under CC BY-NC.
  • One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial Diabetes, obesity & metabolism, 2015-10 DOI, PubMed 25980900, PMC4744775 In the PMC Open Access subset under CC BY-NC-ND.
  • Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy Journal of clinical pharmacology, 2015-12 DOI, PubMed 25998481

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Finland, Germany, Hungary, India, Ireland, Italy, Malaysia, Mexico, Puerto Rico, Russia, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01336023. Randomized; no masking; primary purpose treatment. Start 2011-05-23 (actual); primary completion 2012-05-24 (actual). Results posted on 2017-06-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Acronym
DUAL™ I
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/liraglutide
Intervention (Drug)
insulin degludec
Intervention (Drug)
liraglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01336023
Content hash
dc5177de8c771b369ef6eff51dce3601127ee319ceb0cb5dfa5e0ce9affe6f3e